Crisaborole: Nonsteroidal Treatment for Atopic Dermatitis
Discover crisaborole: A nonsteroidal PDE4 inhibitor for effective atopic dermatitis management.
Crisaborole is a boron-based phosphodiesterase 4 (PDE-4) inhibitor marketed under the brand name Eucrisa, representing a significant advancement in nonsteroidal topical dermatological therapy. As the first topical PDE-4 inhibitor approved for clinical use, crisaborole offers an effective alternative for patients with mild-to-moderate atopic dermatitis who require steroid-sparing treatment options. This innovative medication modifies the inflammatory cascade underlying atopic dermatitis through a distinct mechanism that differs fundamentally from traditional corticosteroid therapies.
What is Crisaborole?
Crisaborole is a nonsteroidal topical medication specifically designed for the management of atopic dermatitis, commonly known as eczema. The medication is formulated as a 2% ointment containing 20 milligrams of crisaborole per gram. It is indicated for use in patients aged two years and older with mild-to-moderate atopic dermatitis affecting up to 40% of body surface area in some regulatory regions. Unlike corticosteroids, which have been the traditional first-line treatment for decades, crisaborole operates through a completely different pharmacological mechanism, making it an attractive option for patients who cannot tolerate or have failed to respond to steroid therapy.
Mechanism of Action
The therapeutic action of crisaborole centers on the inhibition of the phosphodiesterase 4 (PDE-4) enzyme. Overactive PDE-4 in inflammatory cells contributes significantly to the signs and symptoms of atopic dermatitis. Crisaborole operates through a competitive, reversible mechanism that binds to the bimetal center of the PDE-4 enzyme, thereby inhibiting its activity.
When PDE-4 is inhibited, intracellular cyclic adenosine monophosphate (cAMP) levels increase. Elevated cAMP acts as a negative regulator of pro-inflammatory cytokines, reducing the production and effects of inflammatory mediators. Specifically, crisaborole reduces cytokines including:
- Interleukin-4 (IL-4)
- Interleukin-5 (IL-5)
- Interleukin-13 (IL-13)
- Tumor necrosis factor-alpha (TNF-α)
- Interferon gamma
In atopic dermatitis, patients produce abnormally high levels of cytokines that trigger inflammation visible on the skin. By blocking the release of these inflammatory mediators, crisaborole reduces skin inflammation and alleviates the clinical symptoms associated with the condition. The medication also favorably influences the immune response of regulatory T cells, enhancing the body’s natural ability to control inflammatory responses.
Pharmacokinetics and Absorption
Crisaborole demonstrates favorable pharmacokinetic properties that contribute to its safety profile. When applied topically as an ointment, the medication exhibits good skin penetration while maintaining minimal systemic absorption. This localized action is a critical advantage, as it allows therapeutic benefits to be concentrated at the site of inflammation without significant exposure to systemic circulation.
Clinical studies examining absorption in pediatric subjects aged 2 to 17 years revealed that crisaborole is substantially metabolized into two inactive metabolites when applied twice daily for extended periods. The medication’s limited systemic bioavailability reduces the risk of systemic side effects and drug interactions, making it particularly suitable for use in children and patients who require long-term treatment.
Clinical Efficacy and Evidence
The safety and efficacy of crisaborole have been rigorously evaluated through multiple placebo-controlled clinical trials involving diverse age groups. In two primary efficacy trials conducted in the United States, a total of 1,522 participants ranging from two years to 79 years of age received either crisaborole or placebo twice daily for 28 days. Results demonstrated that participants receiving crisaborole achieved significantly greater clinical response with clear or almost clear skin compared to the placebo group.
Across multiple clinical trials, the efficacy outcomes include:
- Treatment success achieved in approximately 31% to 47% of patients
- Clear or almost clear skin (ISGA score) observed in approximately 49% to 65% of patients
- Improvement in pruritus (itching), erythema (redness), exudation, excoriation, induration, papulation, and lichenification
These outcomes demonstrate that crisaborole provides meaningful clinical benefit for a substantial proportion of patients with atopic dermatitis, supporting its role as an effective therapeutic option in dermatological practice.
Dosage and Administration
Crisaborole is administered as a topical ointment with straightforward dosing instructions designed for patient convenience and compliance. Patients should apply a thin layer of crisaborole ointment 2% to affected areas twice daily. The medication is indicated for use in patients aged two years and older, and there are no specific dosage adjustments recommended for special populations, including elderly patients or those with hepatic or renal impairment, due to minimal systemic absorption.
Safety Profile and Side Effects
Crisaborole demonstrates a favorable safety profile with limited adverse events, primarily localized to the application site. The most common side effect is application site reactions, including burning or stinging sensations. These local reactions are generally mild and often diminish with continued use as the skin acclimates to the medication.
Allergic reactions to crisaborole are rare but possible and may include hypersensitivity manifestations at the application site. The medication’s low systemic absorption minimizes the risk of systemic adverse effects and eliminates many concerns associated with long-term topical corticosteroid use, such as:
- Skin atrophy (thinning)
- Telangiectasia (visible blood vessels)
- Striae (stretch marks)
- Hypothalamic-pituitary-adrenal (HPA) axis suppression
The absence of increased side effects or malignancy risk with long-term use further supports crisaborole’s appeal as a steroid-sparing alternative for chronic inflammatory skin conditions.
Place in Therapy
Crisaborole occupies an important position in the therapeutic algorithm for atopic dermatitis management. As the first topical phosphodiesterase 4 inhibitor approved for clinical use, it is indicated as a second-line option for patients who are refractory to topical corticosteroids or unable to tolerate these medications. The medication serves alongside topical calcineurin inhibitors as a nonsteroidal alternative for patients requiring steroid-sparing therapy.
The strategic positioning of crisaborole reflects several clinical considerations:
- Efficacy comparable to or superior to certain topical corticosteroids in selected patients
- Safety profile superior to long-term topical corticosteroid use
- Suitability for use in sensitive areas where corticosteroid atrophy is a concern
- Appropriate for both acute exacerbations and maintenance therapy
- Compatibility with other atopic dermatitis treatments
Regulatory Approvals and Global Availability
Crisaborole has received approval from multiple regulatory authorities worldwide. In the United States, it is indicated for topical treatment of mild-to-moderate atopic dermatitis in patients three months of age and older. The European Union authorizes crisaborole for treatment of mild-to-moderate atopic dermatitis in patients two years of age and older with body surface area involvement of 40% or less. Crisaborole has also been approved in Australia and New Zealand (2019) on prescription for patients from two years of age with mild-to-moderate atopic dermatitis.
Beyond Atopic Dermatitis: Emerging Uses
While crisaborole is primarily indicated for atopic dermatitis, emerging clinical evidence suggests potential benefits in other inflammatory dermatological conditions. Research has documented successful use in conditions including vitiligo, where PDE-4 inhibition reduces inflammatory cytokines implicated in melanocyte dysfunction, and chronic hand eczema, where retrospective series demonstrated improvement in the majority of cases. Additional reported uses include vulvar leukoplakia, irritant contact dermatitis, and necrobiotic xanthogranuloma, though these applications generally require further clinical investigation to establish efficacy and safety definitively.
Comparison with Alternative Treatments
| Treatment Class | Key Advantages | Key Limitations |
|---|---|---|
| Topical Corticosteroids | Rapid anti-inflammatory effect; inexpensive; extensive experience | Risk of skin atrophy; HPA axis suppression; reduced efficacy with prolonged use |
| Topical Calcineurin Inhibitors | Nonsteroidal; no atrophy risk; suitable for face and intertriginous areas | Black box warning regarding malignancy; costly; limited long-term data in children |
| Crisaborole (PDE-4 Inhibitor) | Nonsteroidal; minimal systemic absorption; no atrophy risk; favorable long-term safety; approved for ages 2+ | Application site burning/stinging; moderate efficacy rate; higher cost; limited use data for severe AD |
Clinical Considerations and Patient Selection
Optimal use of crisaborole requires careful patient selection and appropriate clinical judgment. The medication is best suited for patients with mild-to-moderate atopic dermatitis who have demonstrated inadequate response to or intolerance of topical corticosteroids. Ideal candidates include patients concerned about long-term corticosteroid side effects, those with atopic dermatitis affecting sensitive facial or intertriginous areas, and patients requiring prolonged maintenance therapy.
Prior to initiating crisaborole therapy, clinicians should assess baseline disease severity, review previous treatment responses, identify any hypersensitivity to boron-containing compounds, and counsel patients regarding realistic efficacy expectations. Patients should be informed that application site burning or stinging may occur, particularly with initial applications, and that this typically diminishes with continued use.
Frequently Asked Questions
Q: What is the difference between crisaborole and corticosteroids?
A: Crisaborole is nonsteroidal and works by inhibiting the PDE-4 enzyme to reduce inflammatory cytokines, whereas corticosteroids suppress the entire immune response. Crisaborole carries no risk of skin atrophy or HPA axis suppression associated with long-term corticosteroid use.
Q: Can crisaborole be used in children?
A: Yes, crisaborole is approved for use in children as young as two years of age (three months in the United States) with mild-to-moderate atopic dermatitis. Its safety in pediatric populations has been established through clinical trials.
Q: How long does it take for crisaborole to show results?
A: Clinical trials demonstrated measurable improvement within 28 days of twice-daily application. Individual response times may vary, and optimal results may require continued treatment for several weeks.
Q: Is crisaborole absorbed systemically?
A: Crisaborole has minimal systemic absorption when applied topically, with most drug exposure occurring locally at the site of application. The medication is substantially metabolized into inactive metabolites.
Q: Can crisaborole be used with other atopic dermatitis treatments?
A: Crisaborole can be used alongside other atopic dermatitis therapies, though specific combination regimens should be determined by the treating dermatologist based on individual patient needs and disease characteristics.
Q: What should I do if I experience burning or stinging?
A: Application site burning or stinging is the most common side effect and typically diminishes with continued use. If severe discomfort persists or hypersensitivity develops, contact your healthcare provider.
Conclusion
Crisaborole represents a significant therapeutic advance in the nonsteroidal management of atopic dermatitis. As the first topical phosphodiesterase 4 inhibitor approved for clinical use, it provides an effective, well-tolerated alternative for patients with mild-to-moderate atopic dermatitis who require steroid-sparing treatment. Its favorable pharmacokinetic profile, characterized by minimal systemic absorption and low adverse event incidence, makes it particularly suitable for long-term use and application to sensitive body areas. Clinical trial data demonstrating clear or almost clear skin in nearly half of treated patients, combined with its lack of serious systemic side effects, supports its important role in contemporary dermatological practice. As ongoing research continues to explore its potential in other inflammatory skin conditions, crisaborole’s position as a valuable therapeutic option for atopic dermatitis and potentially other dermatoses appears well-established.
References
- Crisaborole — Wikipedia. https://en.wikipedia.org/wiki/Crisaborole
- A Novel Nonsteroidal Topical Treatment for Atopic Dermatitis — National Institutes of Health (NIH/PMC). 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6600556/
- Crisaborole in Dermatology — Indian Journal of Pharmacy and Dermatology. https://ijpgderma.org/crisaborole-in-dermatology/
- Crisaborole — DermNet New Zealand. https://dermnetnz.org/topics/crisaborole
- Mechanism of Action — EUCRISA (crisaborole) ointment 2% HCP Site. Pfizer. https://eucrisa.pfizerpro.com/mechanism-of-action
Similar Articles
Read full bio of Sneha Tete
